Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ427MR)

This product GTTS-WQ427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ427MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1616MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ9962MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ13447MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3410MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ10989MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ14427MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ3154MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW